Browse our anti-APOA4 (APOA4) Antibodies

Human Apolipoprotein A-IV (APOA4) interaction partners

1. The combination of three proteins - apolipoprotein A-IV, complement factor H-related protein 4 and platelet basic protein - demonstrated the best classification performance for our data for diagnosis of growth hormone defic.

2. ApoA-IV inversely correlates with platelet aggregation.ApoA-IV is an endogenous inhibitor of thrombosis. Aspartic acids 5 and 13 at the N-terminus of apoA-IV are required for binding to alphaIIbbeta3 integrin.

3. The genotype-risk associations were examined between APOA4 (rs5095, rs675, rs5110) and obesity-related phenotypes and other comorbidities in Sucre, Venezuela. There was a higher average waist-hip ratio among rs5095 homozygotes and for conicity index among homozygotes for rs5110.

4. Apolipoprotein L1 and apolipoprotein A-IV and their association with kidney function

5. APOA-IV glycation is associated with coronary artery disease severity in patients with Type 2 Diabetes Mellitus.

6. Renal AApoAIV amyloidosis typically presents with progressive chronic kidney disease and histologically exhibits extensive medullary involvement with sparing of the cortex. The diagnosis is best established by mass spectrometry.

7. These findings indicate that LZIP is a novel modulator of APOA4 expression and hepatic lipid metabolism.

8. Study discovered novel and independent associations of prediabetes and related traits with MASP1, and some evidence for associations with THBS1, GPLD1 and ApoA-IV, suggesting a role for these proteins in the pathophysiology of type 2 diabetes.

9. Analyses of SNP-scores indicate potential causal effects of kidney function and by lesser extent triglycerides on apoA-IV concentrations.

10. Low levels of APOA1, APOC3, and APOA4 are associated with risk of Alzheimer disease.

11. Single nucleotide polymorphisms (Rs7396835) of APOA4 protein did not increase the risk of CHD in the Chinese population.

12. ApoA-IV colocalizes with NR4A1, which suppresses G6Pase and PEPCK gene expression at the transcriptional level, reducing hepatic glucose output and lowering blood glucose.

13. the present findings reveal that High-altitude polycythemia -induced gastric mucosal lesion inspires the protection responses by up-regulating APOA4 and APOC3, and down-regulating GIF.

14. analysis of methylation patterns of the APOA1/C3/A4/A5 cluster that may be directly involved in the transcriptional regulation of this cluster, especially in liver

15. the systematic conversion of conserved prolines to alanine increased the thermodynamic stability of apoA-IV and its propensity to oligomerize

16. transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH

17. human apolipoproteina4 and apolipoproteinc3 genes are suppressed by phorbol myristate acetate in hepatic and intestinal cells

18. Human papillomavirus E5 oncoproteins bind the A4 in endoplasmic reticulum to regulate proliferative ability upon differentiation.

19. The structure of human apolipoprotein A-IV as revealed by stable isotope-assisted cross-linking, molecular dynamics, and small angle x-ray scattering.

20. apoA-IV inhibits hepatic gluconeogenesis by decreasing Glc-6-Pase and PEPCK gene expression through NR1D1.

Pig (Porcine) Apolipoprotein A-IV (APOA4) interaction partners

1. MTTP is regulated by apo A-IV in manner to promote increased packaging of triglyceride into chylomicron core, which may be important in neonatal fat absorption.

2. down-regulation of apolipoprotein A-I and A-IV messages in the liver may be mediated by interleukin 6 and tumor necrosis factor-alpha

3. Hepatocyte nuclear factor 4 alpha (HNF-4 alpha)induces apoliprotein IV gene in response to dietary lipids in the intestine.

4. APOA4 genes with SNPs

Horse (Equine) Apolipoprotein A-IV (APOA4) interaction partners

1. Upregulation of the intestinal apolipoprotein APOA-IV in horses with chronic laminitis was confirmed by western blot.[APOA-IV]

Mouse (Murine) Apolipoprotein A-IV (APOA4) interaction partners

1. Reduced levels of endogenous SRC-1 and apoA-IV expression are responsible for the impaired E2's anorectic action in obese females.

2. This study uncovers an anti-sense lncRNA (APOA4-AS), which is co-expressed with APOA4, and concordantly and specifically regulates APOA4 expression both in vitro and in vivo with the involvement of HuR.

3. Our findings may throw light on the function of ApoA4 in inflammatory responses and acute-phase reactions, as well as the development of SERPINA3 relative diseases.

4. Very Low Density Lipoprotein (VLDL) assembly and CREBH activation play key roles in the response to hepatic steatosis by up-regulating apoA-IV and promoting assembly and secretion of larger, more triglyceride - enriched VLDL particles.

5. It was suggested that increased ileal GPR119 is a potential mechanism by which GLP-1 secretion is enhanced in apoA-IV-/- mice.

6. these data suggest that apoA-IV is not necessary for the metabolic improvements shown with VSG, but also suggest an interesting role for apoA-IV in regulating macronutrient preference and hepatic triglyceride levels.

7. These results reveal ApoA-IV as a novel follicle-associated epithelium-specific marker especially in the upper small intestine of adult mice.

8. transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH

9. apoA-IV inhibits hepatic gluconeogenesis by decreasing Glc-6-Pase and PEPCK gene expression through NR1D1.

10. Hepatic steatosis in mice induces hepatic apoA-IV expression, which in turn promotes lipoprotein particle expansion and reduces hepatic lipid burden without increasing the number of secreted atherogenic apoB-containing lipoprotein particles.

11. Data indicate that plasma lipids, lipid absorption, and microsomal triglyceride transfer protein (MTP), FoxO1, and FoxA2 levels are lower at night and at mealtime in apoAIV-/- mice.

12. a novel function of apoA-IV in the biogenesis of discrete HDL-A-IV particles with the participation of ABCA1 and LCAT

13. peripheral apo AIV requires an intact CCK system and vagal afferents to activate neurons in the hindbrain to reduce food intake

14. results suggest that apoA-IV may provide a therapeutic target for the regulation of glucose-stimulated insulin secretion and treatment of diabetes

15. Data show that ApoA4 is a true target gene of LUMAN in bone marrow-derived DCs (BMDCs).

16. These data suggest that Apoa4 has a previously unknown role in mediating the metabolism of chylomicrons, and therefore may be important in regulating plasma lipid metabolism.

17. apoA-IV may play a unique role in integrating feeding behavior, intestinal lipid absorption, and energy storage

18. ApoA-IV deficiency increases Abeta deposition and results in cognitive damage in the mouse model.

19. ApoA-IV restriction to enterocyte is controlled by a new hormone-response element.

20. Results provide the first direct support for the hypothesis that apolipoprotein A-IV is an endogenous anti-inflammatory protein.